Princeton - Sandoz Inc. today announced the US market introduction of Daptomycin for injection 500 mg, an AP-rated generic version of Cubicin (daptomycin), for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria and certain bloodstream infections, including right-sided infective endocarditis.

Daptomycin is an antibiotic that works by killing bacteria or preventing their growth1, and can be used for difficult to treat infections such as MRSA (methicillin-resistant Staphylococcus aureus) or 'superbug' infections2. It is administered intravenously to patients under the direct supervision of their doctor.3

'We continually strive to increase the value of our institutional portfolio with the addition of critical, high-quality, affordable medicines like Daptomycin, bringing us one step closer to delivering on our growth strategy and realizing our ambition to become the world's leading and most valued generics company,' said Carol Lynch, President, Sandoz Inc. 'Our sales force now has another important offering, further strengthening its arsenal of injectables for patients being treated in the hospital setting.'

The immediate availability of Daptomycin bolsters Sandoz industry-leading portfolio of generic antibiotics, which covers over 50 percent of the antibiotics available worldwide. And it reinforces the Sandoz strategic focus on growing its injectables portfolio and overall offering in the hospital setting.

Disclaimer

This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Contact:

Eric Althoff

Tel: 1-646-438-4335

Email: eric.althoff@novartis.com

(C) 2020 Electronic News Publishing, source ENP Newswire